Iovance Biotherapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 557
- Market Cap
- $3.4B
- Website
- http://www.iovance.com
- Introduction
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patient...
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06566092
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธRutgers Cancer Institute, New Brunswick, New Jersey, United States
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- ๐บ๐ธ
Allegheny Health, Pittsburgh, Pennsylvania, United States
๐บ๐ธUofL Health - Brown Cancer Center, Louisville, Kentucky, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT05727904
- Locations
- ๐ฌ๐ง
Beaston West of Scotland Canter Centre, Glasgow, United Kingdom
๐บ๐ธUniversity of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
๐บ๐ธCity of Hope, Duarte, California, United States
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- Conditions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Registration Number
- NCT05398640
- Locations
- ๐บ๐ธ
Orlando Health Cancer Institute, Orlando, Florida, United States
๐บ๐ธNorthside Hospital, Atlanta, Georgia, United States
๐บ๐ธThe University of Kansas Cancer Center, Westwood, Kansas, United States
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05361174
- Locations
- ๐บ๐ธ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
๐บ๐ธSylvester Comprehensive Cancer Center, Miami, Florida, United States
๐บ๐ธOrlando Health Cancer Institute, Orlando, Florida, United States
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT04614103
- Locations
- ๐ฆ๐บ
Westmead Hospital, Westmead, New South Wales, Australia
๐ฉ๐ชUniversitรคtsklinikum Mannheim, Mannheim, Germany
๐ฌ๐งRoyal Marsden Hospital, Chelsea, England, United Kingdom
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04155710
- Locations
- ๐บ๐ธ
Allegheny Health, Pittsburgh, Pennsylvania, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT03645928
- Locations
- ๐บ๐ธ
University of Colorado, Denver, Colorado, United States
๐ฌ๐งThe Royal Marsden NHS Foundation Trust, London, England, United Kingdom
๐บ๐ธUniversity of Southern California, Los Angeles, California, United States
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Registration Number
- NCT03419559
- Locations
- ๐บ๐ธ
UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Washington Medical Center, Seattle, Washington, United States
๐บ๐ธUniversity of California San Diego, Moores Cancer Center, La Jolla, California, United States
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients with Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT03108495
- Locations
- ๐บ๐ธ
LSU Health Sciences Center, New Orleans, Louisiana, United States
๐บ๐ธThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States